Researchers assessed molecular changes of Tr1 cells through CD46 cytoplasmic tail in patients with lupus nephritis who received intravenous methylprednisone therapy.
Marcus Säemann, MD, talks about the role of SGLT-2 inhibitors and their strong nephroprotective potential that may benefit patients with ANCA-associated vasculitis and lupus nephritis.
Karen Costenbader, MD, provides a roundup of all the exciting and compelling news and research in lupus, as presented at the ACR Convergence 2021.
A complete renal remission duration of more than 18 months was associated with good pregnancy outcomes and lower odds of lupus nephritis relapse.
Investigators examined mortality in patients with lupus nephritis who had all stages of chronic kidney disease.
In a study of patients hospitalized with SLE, Black and Hispanic patients and those of other races had higher rates of lupus nephritis compared with White patients, a study found.
Patients with lupus nephritis should be allow early access to COVID-19 vaccination, according to investigators.
In a survey, more rheumatologists than nephrologists viewed belimumab and voclosporin as a “substantial advance” in lupus nephritis treatment.
Standard therapy for lupus nephritis achieves complete renal response in only 20% to 40% of patients.
Voclosporin acts as an anti-inflammatory agent and also stabilizes podocytes to reduce proteinuria.
